We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Editas Medicine Inc | NASDAQ:EDIT | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.02 | 0.36% | 5.54 | 5.45 | 5.55 | 5.645 | 5.38 | 5.49 | 1,557,143 | 00:33:23 |
From Nov 2023 to May 2024
By Dean Seal
Editas Medicine has agreed to license Vertex Pharmaceuticals its Cas9 gene editing technology for ex vivo gene editing medicines targeted at sickle cell disease and beta thalassemia.
The clinical-stage genome editing company said Wednesday that under the terms of the agreement, Vertex will obtain a non-exclusive license for the technology in medicines targeting the BCL11A gene in the fields of sickle cell disease and beta thalassemia, which includes the cell-based gene therapy Casgevy.
The deal extends Editas' cash runway into 2026, the company said, though it didn't disclose the financial terms of the agreement.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 13, 2023 09:34 ET (14:34 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Editas Medicine Chart |
1 Month Editas Medicine Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
